Sanofi SA
If you can't build the next Ozempic, buy it: Where M&A could be heading in the obesity drug space
Investors are contemplating where and when the next big obesity drug deal will occur. At the moment, Novo Nordisk and Eli Lilly have the growing obesity drug market all to themselves. But given the potential size of this opportunity, which some have put at more than $100 billion by 2030 , other pharmaceuticals companies — […]
Read More
Pfizer’s twice-daily weight loss pill joins a long list of obesity drug flops
Sopa Images | Lightrocket | Getty Images Pfizer’s twice-daily version of its experimental weight loss pill has now joined a long list of other scrapped drugs that aimed to treat obesity but came with unintended consequences. The drugmaker on Friday said it will stop developing the twice-daily treatment, danuglipron, after obese patients taking the drug […]
Read More
CDC expedites release of more doses of infant RSV drug from Sanofi, AstraZeneca amid shortage
A RSV-infected child receives treatment, as RS-Virus infections spread among children at Missio children’s clinic Moenchberg, in Wuerzburg, Germany, December 2, 2022. Heiko Becker | Reuters The Centers for Disease Control and Prevention expedited the release of more than 77,000 additional doses of a new drug designed to protect infants from respiratory syncytial virus amid […]
Read More
French prosecutors investigating Sanofi over probable marketplace manipulation
A brand on the Sanofi exhibition area at the Viva Technological know-how meeting focused to innovation and startups at Porte de Versailles exhibition centre in Paris, France June 15, 2022. Benoit Tessier | Reuters French prosecutors have opened a preliminary investigation into multinational pharmaceutical corporation Sanofi above achievable marketplace manipulation. A judicial source verified to […]
Read More
Sanofi to offer insulin product for $35 to all Americans through GoodRx
Sanofi Lantus brand insulin pens are arranged for a photograph in the Brooklyn borough of New York, U.S., on Friday, April 5, 2019. Alex Flynn | Bloomberg | Getty Images Americans, regardless of their insurance status, can now access Sanofi‘s most widely prescribed insulin for $35 through the prescription drug savings company GoodRx, the companies […]
Read More
New RSV protections for infants hit cost, insurance hurdles in U.S. rollout
A doctor vaccinates an infant against respiratory syncytial virus (RSV) in a treatment room of her paediatric practice. Swen Pförtner | Picture Alliance | Getty Images Two new immunizations promise to protect babies from respiratory syncytial virus – if people can find them. Providers are scrambling to offer Pfizer’s vaccine, Abrysvo, to pregnant patients and […]
Read More
CDC advisors recommend Pfizer maternal RSV vaccine to protect infants
A doctor vaccinates an infant against respiratory syncytial virus (RSV) in a treatment room of her paediatric practice. Swen Pförtner | Picture Alliance | Getty Images The Centers for Disease Control and Prevention’s independent panel of advisors on Friday recommended Pfizer‘s maternal vaccine that protects infants from respiratory syncytial virus, the leading cause of hospitalization […]
Read More
FDA approves Pfizer maternal RSV vaccine for infants
CFOTO | Future Publishing | Getty Images The Food and Drug Administration on Monday approved a vaccine from Pfizer that protects infants from respiratory syncytial virus, the leading cause of hospitalization among babies in the U.S. Pfizer’s RSV shot is already approved and available in the U.S. for older adults. It’s now the second treatment […]
Read More
UK investigates weight loss, diabetes drugs like Wegovy and Ozempic for suicide risks
Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy. Stefan Trumpf | Picture Alliance | Getty Images U.K. health authorities on Wednesday said they are reviewing obesity and diabetes drugs like Novo Nordisk‘s Wegovy and Ozempic after some patients who took the treatments […]
Read More
‘Good price, lower threat, large quality’: BofA names leading Europe shares to beat a recession
Financial institution of America has named several European “leading shares” it claims are of “excellent price, very low hazard” and “superior excellent.” All of them turned up on “economic downturn screens” for July, in a market place BofA explained as a being in a recession model cycle. A model cycle refers to the marriage among […]
Read More